- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Nuvectra™ Announces Pricing of Follow-On Stock Offering
Nuvectra (NASDAQ:NVTR), a neurostimulation medical device company, announced today the pricing of its underwritten follow-on public offering of 2,825,000 shares of its common stock at a price to the public of $8.00 per share. As quoted in the press release: The offering is expected to close on or about February 5, 2018, subject to customary closing …
Nuvectra (NASDAQ:NVTR), a neurostimulation medical device company, announced today the pricing of its underwritten follow-on public offering of 2,825,000 shares of its common stock at a price to the public of $8.00 per share.
As quoted in the press release:
The offering is expected to close on or about February 5, 2018, subject to customary closing conditions. In addition, Nuvectra has granted the underwriters a 30-day option to purchase up to 423,750 additional shares of common stock on the same terms and conditions.
Piper Jaffray is acting as sole book-running manager for the offering. JMP Securities and SunTrust Robinson Humphrey are acting as co-managers.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.